Aurora Cannabis Inc. (the “Company” or “Aurora“) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has completed the restructuring of its balance sheet. The second amended and restated credit facility, which matures on December 31, 2022, and consists of a term loan and revolver, was repaid in full, without penalty and at the Company’s discretion, in the amount of approximately $89 million, including accrued interest.
The repayment results in interest and scheduled principal repayment reductions of approximately $25 million over the next year based on the outstanding balance at the time of repayment. After giving effect to the repayment, the Company’s pro forma cash position was approximately $430 million as of May 31, 2021.
“We are pleased to have completed our balance sheet restructuring through the full repayment of our credit facility. Since assuming the CEO role late last year, I recognized having a strong balance sheet is critical in what is a very dynamic industry. Delivering on this priority allows us the ability to operate the business and pursue growth opportunities unconstrained by our balance sheet. Let me also express our appreciation to Aurora’s lenders who have provided us with exceptional support throughout this process,” stated Miguel Martin, Chief Executive Officer of Aurora Cannabis.
“Following this repayment, we continue to have a substantial cash position and the financial flexibility needed to fund current operations and execute our business plan. Further, to maximize our strategic opportunities including within the U.S., we have an at-the-market equity program to issue and sell up to US$300 million of common shares. We are not expecting to access the ATM Program without an accretive use of proceeds,” he concluded.